๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Advanced ER+/HER2- Breast Cancer

Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor NCT05933395Phase 21 site๐Ÿ“ Lebanon Dartmouth-Hitchcock Medical Center ยท Tests: Fulvestrant, Neratinib, Alpelisib, Everolimus, Abemaciclib Elacestrant in Patients With ER+ HER2- ESR1-mutated Locally Advanced or Metastatic Breast Cancer NCT07563595n/a3 sites๐Ÿ“ Freiburg im Breisgau๐Ÿ“ Paderborn๐Ÿ“ Ravensburg iOMEDICO AG ยท Tests: Elacestrant, Standard of care (Investigator Choice) A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors NCT07318805Phase 113 sites๐Ÿ“ Duarte๐Ÿ“ Grand Rapids๐Ÿ“ Long Island City Pfizer ยท Tests: PF-08032562, Fulvestrant, Cetuximab, Fluorouracil, Oxaliplatin A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer NCT07100106Phase 1, Phase 277 sites๐Ÿ“ Huntsville๐Ÿ“ Tucson๐Ÿ“ Duarte Genentech, Inc. ยท Tests: GDC-4198, Giredestrant, Abemaciclib A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC NCT07002177Phase 1, Phase 21 site๐Ÿ“ Shanghai Forward Pharmaceuticals Co., Ltd. ยท Tests: FWD1802, Palbociclib 125mg, Ribociclib 200Mg Oral Tablet, Abemaciclib 150 MG, Everolimus 10 mg Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study NCT06805812n/a24 sites๐Ÿ“ Aviano๐Ÿ“ Brescia๐Ÿ“ Catania Fondazione IRCCS Istituto Nazionale dei Tumori, Milano ยท Tests: Palbociclib, Ribociclib, Abemaciclib A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. NCT07062965Phase 3433 sites๐Ÿ“ Anchorage๐Ÿ“ Chandler๐Ÿ“ Gilbert Pfizer ยท Tests: PF-07248144, Fulvestrant, Everolimus, Exemestane Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer NCT06062498Phase 23 sites๐Ÿ“ Chicago๐Ÿ“ Chicago๐Ÿ“ Chicago Northwestern University ยท Tests: elacestrant, palbociclib, abemaciclib, ribociclib A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer NCT04872166Phase 16 sites๐Ÿ“ Lake Mary๐Ÿ“ Sarasota๐Ÿ“ Cincinnati Edgewood Oncology Inc. ยท Tests: BTX-A51 Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs. NCT06590857Phase 1, Phase 231 sites๐Ÿ“ Phoenix๐Ÿ“ Irvine๐Ÿ“ San Diego RayzeBio, Inc. ยท Tests: RYZ101, Standard of Care Endocrine Therapy A Study of Neoadjuvant TCHpy๏ผˆPyrotinib ๏ผŒTrastuzumab๏ผŒCarboplatin and Paclitaxel๏ผ‰for ER+/HER2+ Breast Cancer NCT06000917Phase 22 sites๐Ÿ“ Wuhan๐Ÿ“ Wuhan Union Hospital, Tongji Medical College, Huazhong Universityโ€ฆ ยท Tests: pyrotinib,Trastuzumab๏ผŒcarboplatin๏ผŒAlbumin paclitaxel Phase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer Patients NCT07235176Phase 1, Phase 21 site๐Ÿ“ Shanghai Qilu Pharmaceutical Co., Ltd. ยท Tests: QLS1304 tablet+Fulvestrant or QLC1401, QLS1304 tablet+Fulvestrant๏ผŒAI or QLC1401+CDK4/6i Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC NCT06263543Phase 23 sites๐Ÿ“ Miami๐Ÿ“ Atlanta๐Ÿ“ Fairway Reshma L. Mahtani, D.O. ยท Tests: Sacituzumab govitecan A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer NCT07647328Phase 389 sites๐Ÿ“ Duarte๐Ÿ“ Palo Alto๐Ÿ“ Marietta AstraZeneca ยท Tests: Camizestrant, Ribociclib Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2) NCT06757634Phase 3239 sites๐Ÿ“ Jonesboro๐Ÿ“ Little Rock๐Ÿ“ Duarte Celcuity Inc ยท Tests: Arm A: Gedatolisib + Palbociclib + Fulvestrant, Arm B: Ribociclib + Fulvestrant, Arm C: Gedatolisib + Palbociclib + Letโ€ฆ Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer NCT07427394Phase 26 sites๐Ÿ“ St Louis๐Ÿ“ East Providence๐Ÿ“ Nashville AstraZeneca ยท Tests: Camizestrant, Atirmociclib Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC NCT06500208Phase 21 site๐Ÿ“ Shanghai Shanghai Jiao Tong University School of Medicine ยท Tests: Adebrelimab combined with nab-paclitaxel, epirubicin and cyclophosphamide A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer NCT06954961Phase 32 sites๐Ÿ“ Beijing๐Ÿ“ Harbin InventisBio Co., Ltd ยท Tests: D-0502, Fulvestrant A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC. NCT06064812Phase 1, Phase 222 sites๐Ÿ“ Hefei๐Ÿ“ Guangzhou๐Ÿ“ Huizhou Forward Pharmaceuticals Co., Ltd. ยท Tests: FWD1802 A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer NCT05187832Phase 11 site๐Ÿ“ Nashville Kind Pharmaceuticals LLC ยท Tests: AND019 PO QD The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) NCT04585750Phase 1, Phase 276 sites๐Ÿ“ Irvine๐Ÿ“ La Jolla๐Ÿ“ Los Angeles PMV Pharmaceuticals, Inc ยท Tests: rezatapopt, pembrolizumab Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer NCT04965766Phase 211 sites๐Ÿ“ Dijon๐Ÿ“ Limoges๐Ÿ“ Lyon Gustave Roussy, Cancer Campus, Grand Paris ยท Tests: U3-1402 A Phase โ…ข Study of Hemay022 in Combination With AI In Advanced Breast Cancer NCT06313983Phase 31 site๐Ÿ“ Beijing Tianjin Hemay Pharmaceutical Co., Ltd ยท Tests: Hemay022+AI, Lapatinib+Capecitabine A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors NCT07540572Phase 111 sites๐Ÿ“ Plantation๐Ÿ“ East Brunswick๐Ÿ“ Lake Success IDEAYA Biosciences ยท Tests: IDE574, Fulvestrant injection Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrine Therapy in ER Middle-low-expression/HER2-negative Advanced Breast Cancer (Rachel) NCT06656624Phase 21 site๐Ÿ“ Nanjing The First Affiliated Hospital with Nanjing Medical Universiโ€ฆ ยท Tests: Ribociclib combined with AIยฑOFS, physician's choice of chemotherapy sequential Ribociclib combined with AIยฑOFS A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast Cancer NCT07766018Phase 219 sites๐Ÿ“ Chiba๐Ÿ“ Fukuoka๐Ÿ“ Fukuoka Stemline Therapeutics, Inc. ยท Tests: Elacestrant Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. NCT06382948Phase 3104 sites๐Ÿ“ Innsbruck๐Ÿ“ Linz๐Ÿ“ Schwaz MedSIR ยท Tests: Everolimus, Elacestrant, Placebo, Auxiliary Medicinal Product - Dexamethasone, Auxiliary Medicinal Product - Luteinizinโ€ฆ Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer NCT07085767Phase 3200 sites๐Ÿ“ Hot Springs๐Ÿ“ Beverly Hills๐Ÿ“ La Jolla Olema Pharmaceuticals, Inc. ยท Tests: Palazestrant, Letrozole-matching placebo, Ribociclib, Letrozole, Palazestrant matching-placebo A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors NCT07029399Phase 118 sites๐Ÿ“ Duarte๐Ÿ“ La Jolla๐Ÿ“ Denver NiKang Therapeutics, Inc. ยท Tests: NKT5097 CDK2/CDK4 dual degrader, Fulvestrant, Letrozole PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA) NCT07222215Phase 21 site๐Ÿ“ Boston Kristina A. Fanucci ยท Tests: Capecitabine, Elacestrant
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy